Pharsight

Redhill patents expiration

1. Aemcolo patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8263120 REDHILL Oral antimicrobial pharmaceutical compositions
May, 2025

(1 year, 12 days from now)

US8486446 REDHILL Oral antimicrobial pharmaceutical compositions
May, 2025

(1 year, 12 days from now)

US8741948 REDHILL Oral antimicrobial pharmaceutical compositions
May, 2025

(1 year, 12 days from now)

US8529945 REDHILL Oral antimicrobial pharmaceutical compositions
May, 2025

(1 year, 12 days from now)

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Nov 16, 2023
Generating Antibiotic Incentives Now(GAIN) Nov 16, 2028

Drugs and Companies using RIFAMYCIN SODIUM ingredient

NCE-1 date: 17 November, 2027

Market Authorisation Date: 16 November, 2018

Treatment: Treatment of travelers' diarrhea caused by non-invasive strains of escherichia coli in adults

Dosage: TABLET, DELAYED RELEASE;ORAL

More Information on Dosage

AEMCOLO family patents

Family Patents

2. Talicia patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9498445 REDHILL Pharmaceutical compositions for the treatment of Helicobacter pylori
Feb, 2034

(9 years from now)

US9603806 REDHILL Pharmaceutical compositions for the treatment of Helicobacter pylori
Feb, 2034

(9 years from now)

US9050263 REDHILL Pharmaceutical compositions for the treatment of Helicobacter pylori
Feb, 2034

(9 years from now)

US11135172 REDHILL Rifabutin-based compositions and methods for treating Helicobacter pylori infection
Feb, 2034

(9 years from now)

US10238606 REDHILL Pharmaceutical compositions for the treatment of Helicobacter pylori
Feb, 2034

(9 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Product(NP) Nov 01, 2022
Generating Antibiotic Incentives Now(GAIN) Nov 01, 2027

Drugs and Companies using AMOXICILLIN; OMEPRAZOLE MAGNESIUM; RIFABUTIN ingredient

Market Authorisation Date: 01 November, 2019

Treatment: Treatment of h. pylori infection in adults

Dosage: CAPSULE, DELAYED RELEASE;ORAL

More Information on Dosage

TALICIA family patents

Family Patents